Received Feb 6, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Dose reconstituted with unapproved diluent administered/Priorix reconstituting the lyophilized component with sterile water for vaccines from instead of the approved diluent; Dose reconstituted with unapproved diluent administered/Priorix reconstituting the lyophilized component with sterile water for vaccines from instead of the approved diluent; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate dose of vaccine administered in a female patient who received MMR (Priorix) for prophylaxis. On 03-FEB-2026, the patient received Priorix. On 03-FEB-2026, an unknown time after receiving Priorix, the patient experienced inappropriate dose of vaccine administered (Verbatim: Dose reconstituted with unapproved diluent administered/Priorix reconstituting the lyophilized component with sterile water for vaccines from instead of the approved diluent) and wrong solution used in drug reconstitution (Verbatim: Dose reconstituted with unapproved diluent administered/Priorix reconstituting the lyophilized component with sterile water for vaccines from instead of the approved diluent). The outcome of the inappropriate dose of vaccine administered and wrong solution used in drug reconstitution were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 04-FEB-2026 The reporter did not have lot number for the vaccine, initials, date of birth or age of the patient. The batch number was not provided, and unable to contact the reporter.